<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-5">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: <br />maintained response after eltrombopag discontinuation
			</div>


			<div class="content-container">

				<ul>
					<li><span>The median duration of response to eltrombopag was 14.8 months (range 3–42 months; evaluable in 12 of 17 patients)<sup>1</sup></span></li>
					<li><span>Patients were able to taper and discontinue eltrombopag treatment if they met the trilineage haematopoiesis criteria for more than 8 weeks with no additional treatment for SAA:<sup>1</sup></span>
						<ul>
							<li><span>Platelet count >50×10<sup>9</sup>/l</span></li>
							<li><span>Haemoglobin >10 g/dl</span></li>
							<li><span>Neutrophil count >1×10<sup>9</sup>/l</span></li>
						</ul>
					</li>
					<li><span>As of the study clinical cut-off date, four patients met the trilineage response criteria and maintained this response (median follow-up of 8.1 months; range 7.2–10.6 months)</span></li>
					<li><span>Absolute pre-treatment reticulocyte count was the only significant predictor of response to eltrombopag<sup>2</sup></span>
						<ul>
							<li><span>Responders versus non-responders (41.8% vs 24.2%, respectively; p=0.023)</span></li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: maintained response after eltrombopag discontinuation</header>
				
			<ul>
				<li><span>Factors that were not predictive of response to eltrombopag treatment were: age, neutrophil count, age-adjusted telomere length, number of prior cycles of immunosuppression, time since last cycle of immunosuppression and aplastic anaemia duration<sup>2</sup></span></li>
				<li><span>Three patients were no longer responsive to treatment during the extension phase (after 16 weeks)<sup>2</sup></span>
					<ul>
						<li><span>One patient required recommencement of RBC transfusions, the second underwent a haplo-cord transplant and the third had an infectious episode after loss of a neutrophil response</span></li>
					</ul>
				</li>
				<li><span>Quality of life analysis showed that there were no significant changes in pre- versus post-eltrombopag physical or mental scores<sup>2</sup></span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523; 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Desmond R <i>et al. Blood</i> 2014;123:1818</span></li>
			</ul>

		</div>


		

	</div>
</div>